(Q38053455)

27 August 2017

title

Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis (English)

1 reference

27 August 2017

J Leman

1

1 reference

27 August 2017

A D Burden

series ordinal

2

1 reference

27 August 2017

language of work or name

English

0 references

publication date

1 November 2012

1 reference

British Journal of Dermatology

27 August 2017

published in

1 reference

27 August 2017

volume

167 Suppl 3

1 reference

27 August 2017

page(s)

12-20

1 reference

Advances in the treatment of moderate-to-severe plaque psoriasis

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11209.X

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11209.X

Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11209.X

Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11209.X

Efficacy and safety of etanercept in psoriasis/psoriatic arthritis: an updated review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11209.X

Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11209.X

The impact of methodological approaches for presenting long-term clinical data on estimates of efficacy in psoriasis illustrated by three-year treatment data on infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11209.X

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11209.X

Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11209.X

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11209.X

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11209.X

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11209.X

Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11209.X

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11209.X

The British Association of Dermatologists' Biologic Interventions Register (BADBIR): design, methodology and objectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11209.X

Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11209.X

Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11209.X

Paradoxical worsening of psoriasis when switching from etanercept to adalimumab: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11209.X

Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11209.X

Adalimumab treatment for severe recalcitrant chronic plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11209.X

Adalimumab for psoriasis: practical experience in a U.K. tertiary referral centre.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11209.X

Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11209.X

Switching between antitumour necrosis factor alpha biologic agents--is patient weight an important consideration?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11209.X

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11209.X

Observational case series on a group of patients with severe psoriasis who failed to respond to antitumour necrosis factor alpha biologics and switched to ustekinumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11209.X

Responses to ustekinumab in the anti-TNF agent-naïve vs. anti-TNF agent-exposed patients with psoriasis vulgaris.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11209.X

British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11209.X

DAS-28-based EULAR response and HAQ improvement in rheumatoid arthritis patients switching between TNF antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2012.11209.X

10.1111/J.1365-2133.2012.11209.X

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference